AU2017263850A1 - Treating of side-effects resulting from Chemodenervation - Google Patents

Treating of side-effects resulting from Chemodenervation Download PDF

Info

Publication number
AU2017263850A1
AU2017263850A1 AU2017263850A AU2017263850A AU2017263850A1 AU 2017263850 A1 AU2017263850 A1 AU 2017263850A1 AU 2017263850 A AU2017263850 A AU 2017263850A AU 2017263850 A AU2017263850 A AU 2017263850A AU 2017263850 A1 AU2017263850 A1 AU 2017263850A1
Authority
AU
Australia
Prior art keywords
chemodenervation
treating
effects resulting
muscle
anticholinesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017263850A
Other languages
English (en)
Inventor
Mary GARDNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delnova Inc
Original Assignee
Delnova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delnova Inc filed Critical Delnova Inc
Publication of AU2017263850A1 publication Critical patent/AU2017263850A1/en
Priority to AU2023201832A priority Critical patent/AU2023201832A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
AU2017263850A 2016-05-13 2017-05-15 Treating of side-effects resulting from Chemodenervation Abandoned AU2017263850A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023201832A AU2023201832A1 (en) 2016-05-13 2023-03-24 Treating of side-effects resulting from chemodenervation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662336344P 2016-05-13 2016-05-13
US62/336,344 2016-05-13
PCT/US2017/032636 WO2017197382A1 (en) 2016-05-13 2017-05-15 Treating of side-effects resulting from chemodenervation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023201832A Division AU2023201832A1 (en) 2016-05-13 2023-03-24 Treating of side-effects resulting from chemodenervation

Publications (1)

Publication Number Publication Date
AU2017263850A1 true AU2017263850A1 (en) 2018-11-22

Family

ID=60266879

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017263850A Abandoned AU2017263850A1 (en) 2016-05-13 2017-05-15 Treating of side-effects resulting from Chemodenervation
AU2023201832A Abandoned AU2023201832A1 (en) 2016-05-13 2023-03-24 Treating of side-effects resulting from chemodenervation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023201832A Abandoned AU2023201832A1 (en) 2016-05-13 2023-03-24 Treating of side-effects resulting from chemodenervation

Country Status (10)

Country Link
US (2) US11129822B2 (https=)
EP (1) EP3454855B1 (https=)
JP (4) JP2019515052A (https=)
KR (2) KR20190008225A (https=)
CN (2) CN109414434A (https=)
AU (2) AU2017263850A1 (https=)
BR (1) BR112018073388A2 (https=)
CA (1) CA3023408A1 (https=)
IL (1) IL262916A (https=)
WO (1) WO2017197382A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502981A (ja) * 2017-11-15 2021-02-04 デルノバ・インコーポレイテッドＤｅｌＮｏｖａ，Ｉｎｃ． ボツリヌス治療の副作用の処置
WO2025226839A2 (en) * 2024-04-23 2025-10-30 New York University Auf1 compositions and methods for promoting generation of neuromuscular junctions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925856A (en) * 1987-07-28 1990-05-15 Sri International Aldoxime-substituted imidazolium derivatives useful in the treatment of poisoning by phosphorus-containing chemicals
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
EP0619814A1 (en) * 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
GB9410871D0 (en) * 1994-05-31 1994-07-20 Imperial College Modification of tetanus toxin for use as a transport protein
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6759552B2 (en) * 2002-03-28 2004-07-06 Council Of Scientific And Industrial Research Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
CN1260349C (zh) * 2003-04-29 2006-06-21 云南省微生物研究所 南宁链霉菌
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US20080090808A1 (en) * 2006-10-17 2008-04-17 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
WO2009036235A2 (en) * 2007-09-12 2009-03-19 Virginia Tech Intellectual Properties, Inc. Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache)
CN101386818B (zh) * 2008-07-29 2011-01-19 中山大学 一种海洋真菌培养物的提取物及其制备方法和应用
JP5782439B2 (ja) * 2009-07-24 2015-09-24 リポテック, エセ.ア.Lipotec, S.A. 筋肉収縮を抑制する化合物
KR101067153B1 (ko) * 2009-10-16 2011-09-22 경상대학교산학협력단 뇌신경 세포 보호 활성 및 아세틸콜린에스테라제 저해 활성을 갖는 율피 추출물 및 그의 용도
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
JP2014520148A (ja) * 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
AU2013312240A1 (en) * 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
LT3157534T (lt) * 2014-06-19 2022-09-12 Attillaps Holdings Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui

Also Published As

Publication number Publication date
EP3454855B1 (en) 2023-12-20
JP2025108527A (ja) 2025-07-23
US20220175753A1 (en) 2022-06-09
IL262916A (en) 2018-12-31
EP3454855A4 (en) 2019-12-25
CN109414434A (zh) 2019-03-01
JP2024099644A (ja) 2024-07-25
JP2022088660A (ja) 2022-06-14
JP2019515052A (ja) 2019-06-06
CN119950719A (zh) 2025-05-09
CA3023408A1 (en) 2017-11-16
US20190183875A1 (en) 2019-06-20
AU2023201832A1 (en) 2023-04-27
WO2017197382A1 (en) 2017-11-16
US11129822B2 (en) 2021-09-28
EP3454855A1 (en) 2019-03-20
BR112018073388A2 (pt) 2019-07-02
KR20190008225A (ko) 2019-01-23
KR20220063197A (ko) 2022-05-17

Similar Documents

Publication Publication Date Title
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
NZ730809A (en) Methods for treating filoviridae virus infections
PH12020550901A1 (en) Macrocyclic compounds for treating disease
HK1251157A1 (zh) 使用ACTRII配体陷阱治疗β-地中海贫血
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
EP4414030A3 (en) Treatment of fragile x syndrome with cannabidiol
AU2020231934A8 (en) Compounds useful in HIV therapy
PH12019500177A1 (en) Treatment and prevention of sleep disorders
WO2016176279A8 (en) Uses of cannabidiol for treatment of infantile spasms
MY202135A (en) Uses of neuroactive compounds
HK1253581A1 (zh) 经取代的吡啶及使用方法
MY201080A (en) Nlrp3 modulators
WO2018191482A3 (en) Methods of treating developmental encephalopathies
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
CA2881554C (en) Methods for inhibiting fascin
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
AU2018337076A1 (en) Method of treatment
ZA202002936B (en) Phenoxy acids for the treatment of neuromuscular disorders
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
AU2017263850A1 (en) Treating of side-effects resulting from Chemodenervation
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted